Talwar Thakore & Associates advised Quadria Capital, a private equity fund focused on Asian healthcare, on its $100 million acquisition of a minority stake in Aragen Life Sciences. Shardul Amarchand Mangaldas & Co. represented Aragen in the transaction.
Goldman Sachs, an existing investor, was advised by Trilegal for this deal.
The investment values Quadria at approximately $1.4 billion, primarily through a fresh capital infusion, with a smaller portion coming from the sale of shares by existing investors. With this investment, Quadria joins Goldman Sachs as the second strategic investor in Aragen.
This funding will support Aragen’s strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe.
In 2024, the pharmaceutical, healthcare, and biotech sectors achieved a total deal value of $3.8 billion, largely driven by high-value transactions and substantial private equity investments, which accounted for 68 percent of the volume and 65 percent of the total value, according to insights from Grant Thornton.
The TT&A team was led by partners Gautam Saha and Amrita Patnaik and included managing associate Ambika Sahai and senior associate Aditi Somani. Managing associate Garvita Mehrotra also assisted on the deal.
The SAM transaction team was led by partners Karun Prakash and Sangamitra Sankaraiah, and included senior associates Aditya Yadav and Hitakshi Mahendru, along with associate Janavi Venkatesh. The SAM due diligence team was also led by partners Prakash, Sankaraiah, and Kriti Kaushik.
The Trilegal team advising Goldman Sachs comprised partner Pranav Atit, counsel Vinit Patwari, senior associate Mansi Jain and associates Meher Dhingra, Janeesha Singh, and Vaishnavi Patel.
